Published in Rheumatology (Oxford) on January 01, 2001
Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis (2004) 1.30
Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset. Rev Diabet Stud (2004) 1.08
Scleroderma lung disease. Eur Respir Rev (2013) 1.04
Immunotherapy of systemic sclerosis. Immunotherapy (2010) 1.03
Corticosteroids and the risk of scleroderma renal crisis: a systematic review. Rheumatol Int (2010) 1.03
Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis (2011) 0.96
Treatment of early diffuse systemic sclerosis skin disease. Clin Exp Rheumatol (2013) 0.91
Lung involvement in systemic sclerosis. Presse Med (2010) 0.90
A review of health utilities across conditions common in paediatric and adult populations. Health Qual Life Outcomes (2010) 0.88
Nailfold videocapillaroscopy micro-haemorrhage and giant capillary counting as an accurate approach for a steady state definition of disease activity in systemic sclerosis. Arthritis Res Ther (2014) 0.81
Safety and effectiveness of mycophenolate in systemic sclerosis. A systematic review. PLoS One (2015) 0.81
Predictors of health-related quality of life and fatigue in systemic sclerosis: evaluation of the EuroQol-5D and FACIT-F assessment tools. Clin Rheumatol (2012) 0.79
Resolution of pansclerotic morphea after treatment with antithymocyte globulin. Nat Rev Rheumatol (2009) 0.78
Efforts to prevent and halt autoimmune beta cell destruction. Endocrinol Metab Clin North Am (2010) 0.78
Enteric-coated mycophenolate sodium for progressive systemic sclerosis--a prospective open-label study with CT histography for monitoring of pulmonary fibrosis. Clin Rheumatol (2013) 0.76
Anti-thymocyte globulin in scleroderma. Rheumatology (Oxford) (2001) 0.75
[Treatment of systemic sclerosis]. Z Rheumatol (2006) 0.75
METABOLIC OBSERVATIONS. Ann Surg (1943) 4.41
CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem (2001) 3.28
Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) (2004) 3.12
Evaluation of polymerase chain reaction for diagnosis of pneumococcal pneumonia. J Clin Microbiol (1993) 3.04
Understanding AIDS-risk behavior among adolescents in psychiatric care: links to psychopathology and peer relationships. J Am Acad Child Adolesc Psychiatry (2001) 2.87
Family study of the major histocompatibility complex in patients with systemic lupus erythematosus: importance of null alleles of C4A and C4B in determining disease susceptibility. Br Med J (Clin Res Ed) (1983) 2.86
Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis (2003) 2.85
A disease severity scale for systemic sclerosis: development and testing. J Rheumatol (1999) 2.85
Circulating endothelin-1 levels in systemic sclerosis subsets--a marker of fibrosis or vascular dysfunction? J Rheumatol (1994) 2.76
The specificity of fetal IgM: antibody or anti-antibody? Ann N Y Acad Sci (1975) 2.65
Antibody-dependent cell-mediated cytotoxicity to target cells infected with type 1 and type 2 herpes simplex virus. J Immunol (1976) 2.49
European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis (2001) 2.49
The promise of integrated representative surveys about sexually transmitted diseases and behavior. Sex Transm Dis (1997) 2.44
EXTRASKELETAL OSSIFYING TUMORS. Ann Surg (1941) 2.39
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum (2010) 2.37
Association of phenotypic and genotypic characteristics of invasive Streptococcus pyogenes isolates with clinical components of streptococcal toxic shock syndrome. Infect Immun (1993) 2.32
Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis (2006) 2.28
THE EARLY AND REMOTE EFFECTS OF TOTAL AND PARTIAL PARAVERTEBRAL SYMPATHECTOMY ON BLOOD PRESSURE: AN EXPERIMENTAL STUDY. Ann Surg (1937) 2.17
Evaluation of bias in diagnostic-test sensitivity and specificity estimates computed by discrepant analysis. J Clin Microbiol (1998) 2.14
Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM (2007) 2.14
Ultrasonography of entheseal insertions in the lower limb in spondyloarthropathy. Ann Rheum Dis (2002) 2.11
Role of superoxide dismutase and catalase as determinants of pathogenicity of Nocardia asteroides: importance in resistance to microbicidal activities of human polymorphonuclear neutrophils. Infect Immun (1985) 2.06
Evaluation of nucleic acid amplification tests as reference tests for Chlamydia trachomatis infections in asymptomatic men. J Clin Microbiol (2000) 2.02
Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol (1997) 2.00
Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis. Rheumatology (Oxford) (2006) 1.94
Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis (2000) 1.89
Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. N Engl J Med (1989) 1.85
Childhood-onset scleroderma: is it different from adult-onset disease. Arthritis Rheum (1996) 1.85
Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases. Clin Exp Immunol (1988) 1.83
Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford) (2008) 1.83
Comparison of arbitrarily primed polymerase chain reaction, ribotyping, and monoclonal antibody analysis for subtyping Legionella pneumophila serogroup 1. J Clin Microbiol (1993) 1.82
Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) (2001) 1.82
Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (1999) 1.79
Lumbar lordosis: study of patients with and without low back pain. Clin Anat (2003) 1.79
A pilot study of the prevalence of chlamydial infection in a national household survey. Sex Transm Dis (1998) 1.78
Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet (1991) 1.76
Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet (1991) 1.76
Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J Biol Chem (2000) 1.74
Studies on Leydig cell physiology and pathology: secretion and metabolism of testosterone. Recent Prog Horm Res (1966) 1.74
Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart (2005) 1.73
Evaluation of thirty-one mouse monoclonal antibodies to human IgG epitopes. Hybridoma (1984) 1.67
Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol (1998) 1.66
The source and role of RANTES in interstitial lung disease. Eur Respir J (1997) 1.62
Typing of Chlamydia trachomatis strains from urine samples by amplification and sequencing the major outer membrane protein gene (omp1). Sex Transm Infect (2001) 1.62
Serological markers in progressive systemic sclerosis: clinical correlations. Ann Rheum Dis (1983) 1.55
Immunohistochemical localization of transforming growth factor-beta 1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders. Histopathology (1994) 1.54
The use of infra-red thermography in a rheumatology unit. Br J Rheumatol (1990) 1.53
Use of systemic prophylactic antibiotics with anterior nasal packing in England, UK. Clin Otolaryngol (2006) 1.52
Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol (2001) 1.51
The parasympathetic secretory nerves of the nose of the cat. J Physiol (1973) 1.49
Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med (1994) 1.49
Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol (1997) 1.47
Plasma acid-base patterns in diabetic ketoacidosis. N Engl J Med (1982) 1.47
Doxycycline and azithromycin for prevention of chlamydial persistence or recurrence one month after treatment in women. A use-effectiveness study in public health settings. Sex Transm Dis (1998) 1.46
Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum (1999) 1.45
Progress in systemic sclerosis: a 10-year perspective. Rheumatology (Oxford) (2009) 1.44
Clearance of inhaled technetium-99m-DTPA as a clinical index of pulmonary vascular disease in systemic sclerosis. Eur Respir J (1999) 1.44
Partial Hepatectomy with Intrahepatic Cholangiojejunostomy : A Useful Addition to Technical Methods for the Management of Common Duct Stricture. Ann Surg (1949) 1.44
Suppression of endogenous IL-10 gene expression in dendritic cells enhances antigen presentation for specific Th1 induction: potential for cellular vaccine development. J Immunol (2000) 1.42
Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis (1991) 1.41
Severe pulmonary hypertension and arterial adventitial changes in newborn calves at 4,300 m. J Appl Physiol (1985) (1987) 1.40
Antireticulin antibody in systemic sclerosis. Ann Rheum Dis (1990) 1.40
Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest (2001) 1.39
Five patients who developed systemic sclerosis shortly after episodes of physical trauma. J Rheumatol (1996) 1.38
Anti-PL 4 in patients with systemic lupus erythematosus with severe renal and haematological disease. QJM (1997) 1.38
Enzyme immunoassay to determine exposure to Chlamydia pneumoniae (strain TWAR). J Clin Microbiol (1989) 1.37
Combination chemotherapy for multiple myeloma. Cancer (1972) 1.36
Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) (2001) 1.35
Clinical spectrum of Kawasaki disease in infants younger than 6 months of age. J Pediatr (1986) 1.34
Follow-up after hydatidiform mole: studies using radioimmunoassay for urinary human chorionic gonadotrophin (HCG). J Obstet Gynaecol Br Commonw (1973) 1.34
IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J Clin Invest (1996) 1.34
Addition of monoclonal antibodies specific for Rickettsia akari to the rickettsial diagnostic panel. J Clin Microbiol (1988) 1.32
European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis (2003) 1.32
Role of thrombin in pulmonary fibrosis. Lancet (1995) 1.30
Autocrine overexpression of CTGF maintains fibrosis: RDA analysis of fibrosis genes in systemic sclerosis. Exp Cell Res (2000) 1.30
Route of infection that induces a high intensity of gamma interferon-secreting T cells in the genital tract produces optimal protection against Chlamydia trachomatis infection in mice. Infect Immun (1998) 1.29
Clearance of inhaled 99mTc-DTPA predicts the clinical course of fibrosing alveolitis. Eur Respir J (1993) 1.29
Acidification of phagosomes in murine macrophages: blockage by Nocardia asteroides. J Infect Dis (1986) 1.29
N-terminal connective tissue growth factor is a marker of the fibrotic phenotype in scleroderma. QJM (2005) 1.28
In vivo and in vitro activation of alveolar macrophages by recombinant interferon-gamma. J Immunol (1987) 1.28
The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis. Am Rev Respir Dis (1993) 1.28
Mycoplasma contamination of chlamydiae isolated from clinical specimens. APMIS (1994) 1.24
The peripheral parasympathetic innervation of the cat lacrimal gland. Br J Pharmacol (1970) 1.24
The control of ccn2 (ctgf) gene expression in normal and scleroderma fibroblasts. Mol Pathol (2001) 1.24
High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax (1992) 1.23
Cigarette smoking and epithelial ovarian cancer by histologic type. Obstet Gynecol (2000) 1.22
A STUDY OF THE EFFECTS OF HEMORRHAGE, TRAUMA, HISTAMINE AND SPINAL ANESTHESIA ON THE COMPOSITION OF THE BLOOD WHEN NO FLUIDS ARE INJECTED AND WHEN FLUIDS ARE INTRODUCED INTRAVENOUSLY. J Clin Invest (1932) 1.22
Screening high-risk adolescent males for Chlamydia trachomatis infection. Obtaining urine specimens in the field. Sex Transm Dis (1998) 1.21
Detection and characterization of mouse monoclonal antibodies to epidemic typhus rickettsiae. J Clin Microbiol (1983) 1.21
Microtubule nucleating sites in higher plant cells identified by an auto-antibody against pericentriolar material. J Cell Biol (1985) 1.21
A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases. Ann Rheum Dis (1991) 1.20
Genetic susceptibility to scleroderma-like syndrome induced by vinyl chloride. Lancet (1983) 1.20
The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl. Medicine (Baltimore) (1992) 1.20
Detection of Neisseria gonorrhoeae infection by ligase chain reaction testing of urine among adolescent women with and without Chlamydia trachomatis infection. Sex Transm Dis (1998) 1.19
Localisation of transforming growth factor beta1 and beta3 mRNA transcripts in normal and fibrotic human lung. Thorax (2001) 1.18
The autonomic innervation of the nasal blood vessels of the cat. J Physiol (1974) 1.18
Rapid assessment of sexually transmitted diseases in a sentinel population in Thailand: prevalence of chlamydial infection, gonorrhoea, and syphilis among pregnant women--1996. Sex Transm Infect (1998) 1.18
Effect of virulent and less virulent strains of Nocardia asteroides on acid-phosphatase activity in alveolar and peritoneal macrophages maintained in vitro. J Infect Dis (1983) 1.17
Thyroid-stimulating antibody activity between different immunoglobulin G subclasses. J Clin Invest (1990) 1.17
Systemic sclerosis: an autoantibody mosaic. Clin Exp Immunol (1999) 1.17